[1] |
|
[2] |
QI X L, LI J, CAUSSY C, et al. Epidemiology,screening,and co-management of type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease[J]. Hepatology, 2024. DOI: 10.1097/HEP.0000000000000913.
|
[3] |
XIONG S Z, JIANG W, WANG Y C, et al. Co-designing interventions to strengthen the primary health care system for the management of hypertension and type 2 diabetes in China[J]. Lancet Reg Health West Pac, 2024, 49:101131. DOI: 10.1016/j.lanwpc.2024.101131.
|
[4] |
OSTROMINSKI J W, JEMMA CHO S M, VADUGANATHAN M, et al. Cardiorenal outcomes in middle-aged and older adults with type 1 and type 2 diabetes[J]. J Am Coll Cardiol, 2024, 84(14):1363-1366. DOI: 10.1016/j.jacc.2024.06.024.
|
[5] |
JENKINS D J A, WILLETT W C, YUSUF S, et al. Association of glycaemic index and glycaemic load with type 2 diabetes,cardiovascular disease,cancer,and all-cause mortality:a meta-analysis of mega cohorts of more than 100 000 participants[J]. Lancet Diabetes Endocrinol, 2024, 12(2):107-118. DOI: 10.1016/S2213-8587(23)00344-3.
|
[6] |
|
[7] |
|
[8] |
黄凤英,付瑜,陈璐. 改良肠内营养方案对老年2型糖尿病伴急性脑卒中患者血糖、肠黏膜及免疫功能的影响[J]. 中国老年学杂志,2024,44(15):3609-3613.
|
[9] |
BROWN E, HEERSPINK H J L, CUTHBERTSON D J, et al. SGLT2 inhibitors and GLP-1 receptor agonists:established and emerging indications[J]. Lancet, 2021, 398(10296):262-276. DOI: 10.1016/S0140-6736(21)00536-5.
|
[10] |
CHEN X X, GILES J, YAO Y, et al. The path to healthy ageing in China:a Peking University-Lancet Commission[J]. Lancet, 2022, 400(10367):1967-2006. DOI: 10.1016/S0140-6736(22)01546-X.
|
[11] |
|
[12] |
|
[13] |
GBD 2021 Diseases and Injuries Collaborators. Global incidence,prevalence,years lived with disability(YLDs),disability-adjusted life-years(DALYs),and healthy life expectancy(HALE)for 371 diseases and injuries in 204 countries and territories and 811 subnational locations,1990-2021:a systematic analysis for the Global Burden of Disease Study 2021[J]. Lancet, 2024, 403(10440):2133-2161. DOI: 10.1016/S0140-6736(24)00757-8.
|
[14] |
陈嘉慧,王海博,柯立鑫,等. 1990—2021年中国因非酒精性脂肪性肝炎所致肝癌的疾病负担分析与未来趋势预测研究[J/OL]. 华西医学,2025:1-8.(2025-01-02).
|
[15] |
JIT M, COOK A R. Informing public health policies with models for disease burden,impact evaluation,and economic evaluation[J]. Annu Rev Public Health, 2024, 45(1):133-150. DOI: 10.1146/annurev-publhealth-060222-025149.
|
[16] |
张强,赵文霞,丁韵涵,等. 疾病负担研究的报告标准(STROBOD声明)解读[J]. 中国循证医学杂志,2025:1-8.[2025-02-26].
|
[17] |
SUN P, YU C, YIN L M, et al. Global,regional,and national burden of female cancers in women of child-bearing age,1990-2021:analysis of data from the global burden of disease study 2021[J]. EClinicalMedicine, 2024, 74:102713. DOI: 10.1016/j.eclinm.2024.102713.
|
[18] |
|
[19] |
DENG X X, LI H, ZHONG Y R, et al. Burden of liver cancer attributable to hepatitis B and alcohol globally,in China,and for five sociodemographic index regions from 1990 to 2021:a population-based study[J]. J Clin Transl Hepatol, 2025, 13(1):1-14. DOI: 10.14218/JCTH.2024.00351.
|
[20] |
HUANG D L, LAI H Y, SHI X, et al. Global temporal trends and projections of acute hepatitis E incidence among women of childbearing age:age-period-cohort analysis 2021[J]. J Infect, 2024, 89(4):106250. DOI: 10.1016/j.jinf.2024.106250.
|
[21] |
ZHANG H, ZHOU X D, SHAPIRO M D, et al. Global burden of metabolic diseases,1990-2021[J]. Metabolism, 2024, 160:155999. DOI: 10.1016/j.metabol.2024.155999.
|
[22] |
LEVIN A T, OWUSU-BOAITEY N, PUGH S, et al. Assessing the burden of COVID-19 in developing countries:systematic review,meta-analysis and public policy implications[J]. BMJ Glob Health, 2022, 7(5):e008477. DOI: 10.1136/bmjgh-2022-008477.
|
[23] |
KAUTZKY-WILLER A, LEUTNER M, HARREITER J. Sex differences in type 2 diabetes[J]. Diabetologia, 2023, 66(6):986-1002. DOI: 10.1007/s00125-023-05891-x.
|
[24] |
杨建江. 基于Cox模型和深度生存神经网络对高龄老人余寿的影响因素分析及预测[D]. 上海:上海师范大学,2023.
|
[25] |
LEAN M E, LESLIE W S, BARNES A C, et al. Primary care-led weight management for remission of type 2 diabetes(DiRECT):an open-label,cluster-randomised trial[J]. Lancet, 2018, 391(10120):541-551. DOI: 10.1016/S0140-6736(17)33102-1.
|
[26] |
LI C X, BISHOP T R P, IMAMURA F, et al. Meat consumption and incident type 2 diabetes:an individual-participant federated meta-analysis of 1·97 million adults with 100 000 incident cases from 31 cohorts in 20 countries[J]. Lancet Diabetes Endocrinol, 2024, 12(9):619-630. DOI: 10.1016/S2213-8587(24)00179-7.
|
[27] |
COLLABORATORS G 2 D. Global,regional,and national burden of diabetes from 1990 to 2021,with projections of prevalence to 2050:a systematic analysis for the Global Burden of Disease Study 2021[J]. Lancet, 2023, 402(10397):203-234. DOI: 10.1016/S0140-6736(23)01301-6.
|
[28] |
国家老年医学中心,中华医学会老年医学分会,中国老年保健协会糖尿病专业委员会. 中国老年糖尿病诊疗指南(2024版)[J]. 协和医学杂志,2024,15(4):771-800.
|
[29] |
LU C C, LI X X, YANG K H. Trends in shared decision-making studies from 2009 to 2018:a bibliometric analysis[J]. Front Public Health, 2019, 7:384. DOI: 10.3389/fpubh.2019.00384.
|
[30] |
|
[31] |
|
[32] |
YANG H B, SONG J Y, XU C, et al. Interventional effects of Pueraria oral liquid on T2DM rats and metabolomics analysis[J]. Biomed Pharmacother, 2024, 175:116780. DOI: 10.1016/j.biopha.2024.116780.
|
[33] |
JI H Y, ZHAO X F, CHEN X Y, et al. Jinlida for diabetes prevention in impaired glucose tolerance and multiple metabolic abnormalities:the FOCUS randomized clinical trial[J]. JAMA Intern Med, 2024, 184(7):727-735. DOI: 10.1001/jamainternmed.2024.1190.
|
[34] |
CAO F, LI D P, WU G C, et al. Global,regional and national temporal trends in prevalence for musculoskeletal disorders in women of childbearing age,1990-2019:an age-period-cohort analysis based on the Global Burden of Disease Study 2019[J]. Ann Rheum Dis, 2024, 83(1):121-132. DOI: 10.1136/ard-2023-224530.
|
[35] |
|